ETBX-071 / ImmunityBio - LARVOL DELTA

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc. | Initiation date: Jan 2025 ➔ Jun 2025

Trial initiation date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Immunotherapy Before and After Surgery (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc. | Initiation date: Jan 2025 ➔ May 2025

Trial initiation date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Open-Label, Phase 2 Clinical Trial of Pre-Radiation and Post-Radiation Immunotherapy with N 803, ETBX-071, and M-CENK in Combination with Radiation for Participants with High-Risk Prostate Cancer. (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc.

New P2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Immunotherapy Before and After Surgery (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc.

New P2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: National Cancer Institute (NCI); Active, not recruiting ➔ Completed; Trial completion date: Jan 2025 ➔ Mar 2021

Clinical • Trial completion • Trial completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer (Businesswire) - P1, N=18; NCT03481816; "ImmunityBio...today announced the publication of Phase I data in The Journal of ImmunoTherapy of Cancer (JITC). The publication, titled 'Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/ brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)' highlighted the safety, T-cell immunogenicity, and clinical activity of ImmunityBio’s second-generation human adenovirus (hAd5) in patients with incurable mCRPC...Study Highlights...Median progression-free survival (PFS) was 22 weeks (95% confidence interval: 19.1 to 34). Median overall survival (OS) was not reached, and the 12-month OS probability for all patients was 83.3% (95% confidence interval: 56.8% to 94.3%)."

P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: May 2020 ➔ Jan 2025; Trial primary completion date: May 2020 ➔ Jan 2020

Clinical • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2021 ➔ May 2020; Trial primary completion date: May 2021 ➔ May 2020

Clinical • Trial completion date • Trial primary completion date

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines (clinicaltrials.gov) - P1; N=5; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Suspended ➔ Active, not recruiting

Clinical • Enrollment closed